Wednesday, May 16, 2007 4:30:43 AM
CIBC: Teva will fall 5-10% on Aciphex ruling
Wachovia, American Technology Research: Not acquiring Merck generics is good news for Teva.
Adi Ben-Israel 15 May 07 16:00
The failure of Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) to acquire the generics business of Merck KGaA (XETRA:MRK) is turning out to be beneficial for the share. Yesterday, Citigroup raised its target price for Teva from $46 to $54, saying that the failure was a good for Teva’s shareholders.
Today, American Technology Research Inc. said that Teva has become more attractive for investors now that the Merck KGaA cloud has lifted. The research company believes that the $6.7 billion that Mylan Laboratories Inc. (NYSE:MYL) paid for Merck generics was way too much, and was highly risky.
Wachovia says that Teva’s loss in the Merck KGaA tender more than offsets last week’s US court defeat in the patent case over ulcer treatment Aciphex.
CIBC World Markets breaks with the consensus. It believes that the Aciphex defeat will cause Teva’s share to fall 5-10% over the coming weeks, but stress that this is in fact a correction.
http://www.globes.co.il/serveen/globes/docview.asp?did=1000212048&fid=942
Recent TEVA News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 12:03:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 12:00:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:41:32 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:38:31 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:27:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:23:46 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:20:44 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:17:48 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:14:54 AM
- Adobe Soars 15% Pre-Market; Visa and Mastercard Encounter Hurdles in $30 Billion Agreement, and More • IH Market News • 06/14/2024 11:21:47 AM
- Teva to Present at the Goldman Sachs 45th Annual Global Healthcare Conference • Business Wire • 06/04/2024 08:05:00 PM
- New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate) • Business Wire • 06/01/2024 06:25:00 PM
- Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024 • Business Wire • 06/01/2024 06:20:00 PM
- Teva Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day) • Business Wire • 05/29/2024 10:38:00 PM
- Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S. • Business Wire • 05/21/2024 12:25:00 AM
- Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S. • GlobeNewswire Inc. • 05/21/2024 12:25:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/15/2024 12:36:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 12:30:32 PM
- Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations • Business Wire • 05/15/2024 12:15:00 PM
- Bain Capital in Talks to Acquire PowerSchool; Blackstone Emerges Victorious in Hipgnosis Bidding War, and More News • IH Market News • 05/09/2024 11:53:19 AM
- Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook • Business Wire • 05/08/2024 11:00:00 AM
- Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia • Business Wire • 05/08/2024 10:30:00 AM
- Teva to Present at the 2024 Bank of America Healthcare Conference • Business Wire • 05/02/2024 10:30:00 PM
- Teva’s 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets • Business Wire • 05/02/2024 12:30:00 PM
- U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab) • Business Wire • 04/30/2024 08:00:00 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM